PMID: 16630396Apr 25, 2006Paper

Novel agents in acute myeloid leukemia

The Cancer Journal
Ahmed AribiFrank Giles

Abstract

In the past 40 years, advances in supportive care and development of chemotherapeutic agents have led to improved outcomes in patients with acute myeloid leukemia. High relapse rates following remission have led to extensive efforts to develop techniques and regimens for detecting and eliminating minimal residual disease. However, the best postremission therapy has not been identified. Better understanding of the biology and the molecular pathogenesis of AML has led to the development of new, more specific agents and strategies for AML treatment. Targeted therapy has improved outcomes in some patients. Most of the new agents are less toxic then their predecessors, and they can be used in combination with the more intensive traditional regimens.

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.